We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+0.28%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.95B
AUM Growth
-$468M
Cap. Flow
-$179M
Cap. Flow %
-6.06%
Top 10 Hldgs %
70.08%
Holding
59
New
4
Increased
11
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$58M
2
RVMD icon
Revolution Medicines
RVMD
+$35.5M
3
VERV
Verve Therapeutics
VERV
+$35.3M
4
XNCR icon
Xencor
XNCR
+$33.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$31.5M

Top Sells

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$102M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$58.2M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$44.7M
4
CGON icon
CG Oncology
CGON
+$37.5M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$37M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVA
51
Inventiva
IVA
$1.04B
$1.47M 0.05%
686,040
– –
ENGNW icon
52
enGene Therapeutics Warrants
ENGNW
$3.64M
$804K 0.03%
945,402
– –
NCEL
53
NewcelX Ltd
NCEL
$18.7M
$303K 0.01%
14,368
– –
CGON icon
54
CG Oncology
CGON
$6.21B
– –
-994,596
Closed -$37.5M
IDYA icon
55
IDEAYA Biosciences
IDYA
$3.41B
– –
-1,409,993
Closed -$44.7M
IONS icon
56
Ionis Pharmaceuticals
IONS
$8.56B
– –
-1,451,879
Closed -$58.2M
NAMS icon
57
NewAmsterdam Pharma
NAMS
$3.22B
– –
-1,521,948
Closed -$25.3M
VTGN icon
58
VistaGen Therapeutics
VTGN
$10M
– –
-2,000,000
Closed -$6.02M
MTEM
59
DELISTED
Molecular Templates, Inc.
MTEM
– –
-522,238
Closed -$734K
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2024 Portfolio in Review

As of Q4 2024, BVF Inc held 59 positions worth $2.95B, down 14% from $3.42B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

BVF Inc withdrew a net $179M in Q4 2024, closing 6 positions and reducing 13 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $58.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in Septerna Inc worth $56.2M.

  • BVF Inc's largest Q4 2024 buy was Septerna Inc: 2,452,024 shares worth $56.2M.
  • BVF Inc added most to Revolution Medicines in Q4 2024, an estimated $35.5M increase.
  • BVF Inc's biggest Q4 2024 reduction was MoonLake Immunotherapeutics, cutting an estimated $102M.
  • BVF Inc fully exited Ionis Pharmaceuticals in Q4 2024, selling an estimated $58.2M.
  • BVF Inc's ten largest holdings make up 70% of its $2.95B portfolio in Q4 2024.
  • BVF Inc opened 4 new positions and closed 6 in Q4 2024.
  • BVF Inc's portfolio value fell 14% quarter-over-quarter to $2.95B.

Based on BVF Inc's 13F filing for Q4 2024, filed 14 Feb 2025.